101 (PB091) - Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
| Autor: | Hamilton, E., Meisel, J., Alemany, C., Virginia, B., Lin, N., Wesolowski, R., Mathauda-Sahota, G., Makower, D., Lawrence, J., Faltaos, D., Mitri, Z., Sabanathan, D., Clark, D., Pluard, T., Hui, R., McCarthy, N., Patel, M. |
|---|---|
| Zdroj: | In European Journal of Cancer October 2022 174 Supplement 1:S36-S36 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect